CARLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

CARLSMED, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$13.66+0.25 (+1.86%)

Close on Oct 19, 2026

Market cap: $371.43M
P/E (TTM): –
Dividend yield: –

Dividends

Carlsmed has not reported a dividend

No dividend per share appears in Carlsmed's annual filings since fiscal 2023.

Where these numbers come from

Parsed from the XBRL in Carlsmed's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CARL.

Revenue growth65.4% · median 19.5%

Gross margin76.6% · median 70.8%

Operating margin-61.1% · median -8.3%

Net margin-57.4% · median -13.5%

Company	Revenue	Growth
ATEC	$815.05M	+19.5%
SIBN	$213.60M	+15.3%
XTNT	$109.53M	-14.3%
CARL	$63.30M	+65.4%
SI	$60.06M	+60.9%
APYX	$58.42M	+25.6%

Company

Next earnings (est.): Nov 5, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 24
Held by institutions: 20.9%
Auditor: Ernst & Young LLP
SEC CIK: 1794546

Advertisement
300 × 250